44
70
12
↑44
↓70
—12
Evidence suggests Melatonin maydecreaseInsulin sensitivity.
67 studies (126 claims)
Emerging evidence
Typical effective dose 10 (3–10) mgacross 16 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| decrease in melatonin levels | Increases - leads to an up-regulation of | insulin secretion | HumanAnimal | diabetic rat models | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| decrease in melatonin levels | Increases - leads to an up-regulation of | insulin secretion | HumanAnimal | diabetic rat models | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| melatonin | Affects - exerts its influence | insulin secretion from β-cells | HumanAnimal | islet of Langerhans | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| melatonin | Affects - exerts its influence | insulin secretion from β-cells | HumanAnimal | islet of Langerhans | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| increase in melatonin levels | Decreases - leads to a down-regulation of | insulin secretion | HumanAnimal | diabetic rat models | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| increase in melatonin levels | Decreases - leads to a down-regulation of | insulin secretion | HumanAnimal | diabetic rat models | Not specified | Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. |
| pretreatment of hUC-MSCs with melatonin | Decreases - alleviated | impaired glycemic control and insulin resistance | AnimalMolecular | — | — | Melatonin treatment improves human umbilical cord mesenchymal stem cell therapy in a mouse model of type II diabetes mellitus via the PI3K/AKT signaling pathway. |
| melatonin administration | Decreases - significantly reduced | homeostasis model of assessment-insulin resistance (HOMA-IR) | Human | women with polycystic ovary syndrome (PCOS) | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.cited 58× |
| melatonin administration | Increases - significantly increased | quantitative insulin sensitivity check index (QUICKI) | Human | women with polycystic ovary syndrome (PCOS) | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.cited 58× |
| melatonin administration | Decreases - significantly reduced | serum insulin | Human | women with polycystic ovary syndrome (PCOS) | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Effects of melatonin administration on mental health parameters, metabolic and genetic profiles in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial.cited 58× |
| melatonin administration | Decreases - significantly reduced | homeostasis model of assessment-insulin resistance | Human | diabetic hemodialysis (HD) patients | 2 x 5mg/day (10mg total daily dose), taken 1 hour before bedtime. | The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 39× |
| melatonin administration | Increases - significantly increased | quantitative insulin sensitivity check index | Human | diabetic hemodialysis (HD) patients | 2 x 5mg/day (10mg total daily dose), taken 1 hour before bedtime. | The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 39× |
| melatonin administration | Decreases - significantly reduced | serum insulin levels | Human | diabetic hemodialysis (HD) patients | 2 x 5mg/day (10mg total daily dose), taken 1 hour before bedtime. | The Effects of Melatonin Supplementation on Parameters of Mental Health, Glycemic Control, Markers of Cardiometabolic Risk, and Oxidative Stress in Diabetic Hemodialysis Patients: A Randomized, Double-Blind, Placebo-Controlled Trial.cited 39× |
| melatonin administration | Decreases - significantly reduced | insulin | Human | patients with diabetic nephropathy (DN) | 10 mg/d | Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy.cited 17× |
| melatonin administration | Decreases - significantly reduced | insulin resistance | Human | patients with diabetic nephropathy (DN) | 10 mg/d | Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy.cited 17× |
| melatonin administration | Increases - significantly increased | insulin sensitivity | Human | patients with diabetic nephropathy (DN) | 10 mg/d | Metabolic and Anti-inflammatory Response to Melatonin Administration in Patients with Diabetic Nephropathy.cited 17× |
| Melatonin administration | Decreases - has been shown to inhibit | insulin release | HumanMolecular | pancreatic β-cells | Not specified. | Metabolic syndrome, its pathophysiology and the role of melatonin. |
| Melatonin administration | Decreases - has been shown to inhibit | insulin release | HumanMolecular | pancreatic β-cells | Not specified. | Metabolic syndrome, its pathophysiology and the role of melatonin. |
| Melatonin | Increases - increased | insulin sensitivity | HumanMolecular | animals fed with either high fat or high sucrose diet | Not specified. | Metabolic syndrome, its pathophysiology and the role of melatonin. |
| Melatonin | Increases - increased | insulin sensitivity | HumanMolecular | animals fed with either high fat or high sucrose diet | Not specified. | Metabolic syndrome, its pathophysiology and the role of melatonin. |
| melatonin administration | Increases - increasing | insulin sensitivity | Human | — | 5 mg melatonin tablets twice daily. | Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial.cited 1× |
| melatonin supplementation | No effect - secondary outcomes include changes in | fasting blood sugar and serum insulin | Human | — | 5 mg melatonin tablets twice daily. | Effects of melatonin supplementation on metabolic parameters, oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: study protocol for a double-blind, randomized controlled trial.cited 1× |
| daily melatonin (3 mg) replacement for 3 months | Decreases - decreased | fasting insulin levels | Human | patients with melatonin deficiency (radiotherapy or surgical removal of pineal gland) | 3 mg daily | Melatonin Increases Brown Adipose Tissue Volume and Activity in Patients With Melatonin Deficiency: A Proof-of-Concept Study.cited 37× |
| daily melatonin (3 mg) replacement for 3 months | Decreases - decreased | HOMA of insulin resistance | Human | patients with melatonin deficiency (radiotherapy or surgical removal of pineal gland) | 3 mg daily | Melatonin Increases Brown Adipose Tissue Volume and Activity in Patients With Melatonin Deficiency: A Proof-of-Concept Study.cited 37× |
| high doses of melatonin | Decreases - tendency towards lower | insulin levels in the first minutes after glucose administration | Human | G-allele carriers | Four doses of 10 mg oral melatonin. | Acute metabolic effects of melatonin-A randomized crossover study in healthy young men.cited 17× |
| high doses of melatonin | Decreases - significantly reduced | insulin sensitivity index | Human | whole group | Four doses of 10 mg oral melatonin. | Acute metabolic effects of melatonin-A randomized crossover study in healthy young men.cited 17× |
| high doses of melatonin | Decreases - significantly reduced | insulin sensitivity index | Human | homozygous carriers of the rs10830963 C-allele | Four doses of 10 mg oral melatonin. | Acute metabolic effects of melatonin-A randomized crossover study in healthy young men.cited 17× |
| acute administration of melatonin in supra-physiological doses | Decreases - may have a negative impact | insulin sensitivity | Human | — | Four doses of 10 mg oral melatonin. | Acute metabolic effects of melatonin-A randomized crossover study in healthy young men.cited 17× |
| melatonin | No effect - dependent synchronization | circadian insulin secretion | HumanAnimalMolecular | — | — | New evidence for a role of melatonin in glucose regulation. |
| melatonin | Decreases - interferes in this process by inhibiting | insulin secretion | HumanAnimalMolecular | pancreatic β-cells | — | New evidence for a role of melatonin in glucose regulation. |
| melatonin | No effect - impact on insulin secretion transmitted through | insulin secretion | HumanAnimalMolecular | — | — | New evidence for a role of melatonin in glucose regulation. |
| melatonin | Decreases - reduced slightly | fasting insulin levels | Human | healthy adults or patients with metabolic diseases | Not specified in the abstract. | Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta-analysis.cited 13× |
| melatonin | Decreases - trended towards reduced | insulin resistance (HOMA-IR) | Human | healthy adults or patients with metabolic diseases | Not specified in the abstract. | Effects of daily administration of melatonin before bedtime on fasting insulin, glucose and insulin sensitivity in healthy adults and patients with metabolic diseases. A systematic review and meta-analysis.cited 13× |
| melatonin | Increases - activating | gene expression of insulin-like growth factor-1 | Human | — | Not specified | The effects of melatonin on neurohormonal regulation in cardiac cachexia: A mechanistic review.cited 6× |
| melatonin | Decreases - inhibited | glucagon-stimulated insulin release | AnimalMolecular | INS-1 cells | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | No effect - did not show a significant effect | insulin release | AnimalMolecular | islets from MT(1) knockout and MT(1/2) double-knockout mice | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | Decreases - resulted in a decrease | insulin release | AnimalMolecular | islets of wild-type mice | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | No effect - no melatonin-induced reduction in insulin secretion could be found | insulin secretion | AnimalMolecular | MT(1)-knockdown cells | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | No effect - did not sensitize | insulin secretion | AnimalMolecular | rMT(1)-knockdown cells | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | Decreases - inhibits | insulin secretion | AnimalMolecular | rat INS-1 cells and isolated mouse islets | — | Melatonin influences insulin secretion primarily via MT(1) receptors in rat insulinoma cells (INS-1) and mouse pancreatic islets. |
| melatonin | No effect - unaffected | glucose-stimulated insulin secretion | HumanAnimal | in vivo | Not specified | The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies.cited 5× |
| melatonin | No effect - did not affect | insulin secretion | HumanAnimal | healthy young men | Not specified | The Effect of Melatonin on Incretin Hormones: Results From Experimental and Randomized Clinical Studies.cited 5× |
| melatonin | Increases - acts by regulating expression and/or triggering phosphorylation | GLUT4 expression and insulin receptor signaling | Human | — | Not specified | Melatonin, energy metabolism, and obesity: a review.cited 378× |
| melatonin | Increases - necessary for proper synthesis, secretion, and action | insulin | Human | — | Not specified | Melatonin, energy metabolism, and obesity: a review.cited 378× |
| reduction in melatonin production | Increases - induces | insulin resistance, glucose intolerance, sleep disturbance, metabolic circadian disorganization | Human | during aging, shift-work or illuminated environments during the night | Not specified | Melatonin, energy metabolism, and obesity: a review.cited 378× |
| melatonin | No effect - regulatory effects on | hormone production and insulin sensitivity | Human | PCOS individuals | Not specified | Melatonin: Current evidence on protective and therapeutic roles in gynecological diseases.cited 4× |
| melatonin (1 or 3 mg nightly) | No effect - No significant changes were observed | insulin | Human | postmenopausal women | 1 or 3 mg nightly | Reduced fat mass and increased lean mass in response to 1 year of melatonin treatment in postmenopausal women: A randomized placebo-controlled trial.cited 53× |
| melatonin | No effect - functional link between | insulin | Human | — | Not specified | Diabetes mellitus and melatonin: Where are we?cited 33× |
| melatonin | Increases - induces production | insulin growth factor | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - induces production | insulin growth factor | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - promotes | insulin receptor tyrosine phosphorylation | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - promotes | insulin receptor tyrosine phosphorylation | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Decreases - decreases | insulin secretion | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Decreases - decreases | insulin secretion | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - increases | insulin secretion | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Increases - increases | insulin secretion | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | No effect - induces a phase shift | insulin secretion by the pancreatic islets in a circadian manner | HumanMolecular | pancreatic islets | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | No effect - induces a phase shift | insulin secretion by the pancreatic islets in a circadian manner | HumanMolecular | pancreatic islets | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin supplementation | No effect - restored | glucose intolerance and insulin resistance | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin supplementation | No effect - restored | glucose intolerance and insulin resistance | HumanMolecular | — | Not specified | The role of melatonin in diabetes: therapeutic implications. |
| melatonin | Decreases - revealed an inverse relationship | insulin levels | HumanAnimalMolecular | diabetic rat models | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Decreases - revealed an inverse relationship | insulin levels | HumanAnimalMolecular | diabetic rat models | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | No effect - influences | insulin secretion | HumanAnimalMolecular | in vivo and in vitro | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | No effect - influences | insulin secretion | HumanAnimalMolecular | in vivo and in vitro | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Decreases - likely inhibits | insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Decreases - likely inhibits | insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Increases - increases | insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Increases - increases | insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin levels | Decreases - leads to a decrease | stimulated insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin levels | Decreases - leads to a decrease | stimulated insulin secretion | HumanAnimalMolecular | — | Not specified | Experimental and clinical aspects of melatonin and clock genes in diabetes. |
| melatonin | Decreases - reduces | insulin release | HumanAnimalMolecular | human and rodent islets in vitro | Not specified | Monoamines' role in islet cell function and type 2 diabetes risk.cited 5× |
| melatonin | Decreases - inhibiting action | insulin release | Molecular | — | — | Role of melatonin on diabetes-related metabolic disorders. |
| melatonin | Increases - modulates | insulin release | HumanMolecular | humans | — | Cellular signalling of melatonin and its role in metabolic disorders. |
| Melatonin | Decreases - clinical use of this non-toxic indoleamine in conjunction with other treatments for reducing | insulin resistance | Human | — | Not specified | Glucose: a vital toxin and potential utility of melatonin in protecting against the diabetic state.cited 32× |
| Melatonin | Decreases - eases the effects of | insulin resistance associated with the type 2 diabetic state | Human | patients with type 2 diabetes | Not specified | Glucose: a vital toxin and potential utility of melatonin in protecting against the diabetic state.cited 32× |
| melatonin (MLT) | Decreases - possesses a number of antidiabetic health benefits | insulin resistance | HumanMolecular | in vitro and in vivo studies | Not specified | Melatonin as a Pleiotropic Molecule with Therapeutic Potential for Type 2 Diabetes and Cancer.cited 7× |
| melatonin | Decreases - decreases | insulin resistance | Human | — | Not Assessed | Melatonin: A Molecule for Reducing Breast Cancer Risk.cited 39× |
| melatonin | Decreases - prevention | insulin resistance | Human | — | 2-10mg/day in humans (clinical trials), 100mg/day suggested for cytoprotective effects (animal studies). | Melatonin and healthy aging.cited 37× |
| melatonin | Decreases - ameliorated | insulin resistance | Human | — | Not specified in the abstract. | Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 8× |
| melatonin | Increases - ameliorated | insulin sensitivity | Human | — | Not specified in the abstract. | Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 8× |
| melatonin supplementation | Decreases - significantly reduced | homeostasis model assessment of insulin resistance (HOMA-IR) | Human | 376 participants | Not specified in the abstract. | Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 8× |
| melatonin supplementation | Decreases - significantly reduced | insulin levels | Human | 376 participants | Not specified in the abstract. | Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 8× |
| melatonin supplementation | Increases - increased | quantitative insulin sensitivity check index (QUICKI) | Human | 376 participants | Not specified in the abstract. | Effects of Melatonin Supplementation on Insulin Levels and Insulin Resistance: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 8× |
| melatonin | Decreases - preventing insulin resistance | insulin resistance | Human | — | Suggested effective cytoprotective dose: 100 mg/day; current clinical trial doses: 2-10 mg. | Melatonin as a Chronobiotic and Cytoprotector in Non-communicable Diseases: More than an Antioxidant.cited 3× |
| melatonin | Decreases - counteracting | insulin resistance | HumanAnimal | distinct models of obesity | — | Melatonin acts through MT1/MT2 receptors to activate hypothalamic Akt and suppress hepatic gluconeogenesis in rats. |
| melatonin | Decreases - decreases | insulin secretion | HumanAnimalMolecular | pancreatic β-cells | — | Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonisms in type 1 and type 2 diabetes. |
| melatonin | Decreases - reduces | the plasma insulin level | HumanAnimalMolecular | — | — | Catecholamines are the key for explaining the biological relevance of insulin-melatonin antagonisms in type 1 and type 2 diabetes. |
| melatonin | Decreases - reduced insulin secretion | insulin secretion | Animal | conditions of MT2 overexpression | — | Recent Findings in Melatonin Research and Their Relevance to the CNS. |
| Melatonin | Decreases - reduced | insulin secretion | HumanMolecular | human islet β-cells | — | Supraspinal melatonin MT |
| melatonin | Increases - influence | insulin secretion | Human | in vivo and in vitro | Not specified | Melatonin and glucose metabolism: clinical relevance.cited 31× |
| night-time melatonin levels | Increases - related to | night-time insulin concentrations | Human | patients with diabetes | Not specified | Melatonin and glucose metabolism: clinical relevance.cited 31× |
| melatonin | No effect - influences | insulin secretion | HumanAnimalMolecular | rat and human pancreatic islets, rat insulinoma cells | — | The insulin-melatonin antagonism: studies in the LEW.1AR1-iddm rat (an animal model of human type 1 diabetes mellitus). |
| melatonin | No effect - affects | insulin sensitivity | Human | — | Not specified | Chronomedicine and type 2 diabetes: shining some light on melatonin.cited 44× |
| melatonin | No effect - affects | the insulin secretory activity of the pancreatic beta cell | Human | — | Not specified | Chronomedicine and type 2 diabetes: shining some light on melatonin.cited 44× |
| melatonin | Increases - may increase | insulin sensitivity | Human | — | — | The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?cited 7× |
| consumption close to melatonin peak concentrations | Increases - may induce | insulin resistance | Human | — | — | The Role of Melatonin in Chronic Kidney Disease and Its Associated Risk Factors: A New Tool in Our Arsenal?cited 7× |
| melatonin | Increases - may also be associated with | insulin sensitivity | Human | ICU patients | — | Sleep in the intensive care unit.cited 7× |
| melatonin | Increases - improved | insulin sensitivity | Animal | high-fat diet-induced obese mice | — | New evidence of melatonin receptor contribution to ram sperm functionality. |
| Melatonin | Increases - improved | insulin sensitivity | Human | patients with metabolic syndrome | — | Expression of Melatonin Receptor 1 in Rat Mesenteric Artery and Perivascular Adipose Tissue and Vasoactive Action of Melatonin. |
| Melatonin | Increases - improved | insulin sensitivity | Human | Patients with rare MTNR1B variants | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| Melatonin | Increases - improved | insulin sensitivity | Human | T2D MTNR1B variant carriers | — | Circadian, Sleep and Caloric Intake Phenotyping in Type 2 Diabetes Patients With Rare Melatonin Receptor 2 Mutations and Controls: A Pilot Study. |
| Melatonin | Increases - improved | insulin sensitivity | Human | patients with metabolic syndrome | — | Melanogenesis Is Directly Affected by Metabolites of Melatonin in Human Melanoma Cells. |
| melatonin | Increases - has beneficial effects on | lipid profile and insulin resistance | Human | — | Not specified | Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review.cited 64× |
| melatonin | Increases - has therapeutic mechanisms including | restoring insulin sensitivity | Human | — | Not specified | The role of melatonin in the treatment of type 2 diabetes mellitus and Alzheimer's disease.cited 38× |
| exogenous melatonin | Decreases - were lower | plasma insulin concentrations | Animal | Siberian hamster | Not specified | Effects of cold exposure, exogenous melatonin and short-day treatment on the weight-regulation and body temperature of the Siberian hamster (Phodopus sungorus).cited 18× |
| endogenous melatonin | Decreases - were lower | plasma insulin concentrations | Animal | Siberian hamster | Not specified | Effects of cold exposure, exogenous melatonin and short-day treatment on the weight-regulation and body temperature of the Siberian hamster (Phodopus sungorus).cited 18× |
| long-term melatonin treatment (10 mg daily) | Decreases - decreased | insulin sensitivity | Human | male participants with type 2 diabetes | — | Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial.cited 17× |
| long-term melatonin treatment (10 mg daily) | Decreases - decreased | insulin sensitivity | Human | male patients with type 2 diabetes | — | Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial.cited 17× |
| melatonin treatment | Increases - increased | second-phase insulin response | Human | male participants with type 2 diabetes | — | Three months of melatonin treatment reduces insulin sensitivity in patients with type 2 diabetes-A randomized placebo-controlled crossover trial.cited 17× |
| long-term melatonin treatment | Decreases - diminished | release of insulin | HumanAnimalMolecular | — | — | Calcium-signaling components in rat insulinoma β-cells (INS-1) and pancreatic islets are differentially influenced by melatonin. |
| melatonin 3 mg/day | No effect - did not differ significantly in changes in insulin concentration | insulin concentration | Human | patients with first-episode schizophrenia treated with olanzapine | 3 mg/day | Melatonin for prevention of metabolic side-effects of olanzapine in patients with first-episode schizophrenia: randomized double-blind placebo-controlled study.cited 63× |
| melatonin treatment | Increases - significantly increased | quantitative insulin sensitivity check index | Human | diabetic patients with CHD | 10 mg melatonin (2 capsules of 5 mg each) once daily. | Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.cited 94× |
| melatonin supplementation | Decreases - significantly reduced | homeostasis model of assessment-estimated insulin resistance | Human | diabetic patients with CHD | 10 mg melatonin (2 capsules of 5 mg each) once daily. | Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.cited 94× |
| melatonin supplementation | Decreases - significantly reduced | serum insulin concentrations | Human | diabetic patients with CHD | 10 mg melatonin (2 capsules of 5 mg each) once daily. | Melatonin administration lowers biomarkers of oxidative stress and cardio-metabolic risk in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial.cited 94× |
| myo-inositol plus melatonin | Decreases - decreased | serum insulin | Human | women during menopausal transition | 2 g myo-inositol twice daily (myo-Ins group) or 2 g myo-inositol plus 3 g melatonin daily (combination group). | Myo-inositol and melatonin in the menopausal transition.cited 24× |
| melatonin supplementation | Decreases - had significantly lower | homeostasis model of assessment-insulin resistance | Human | patients under methadone maintenance treatment (MMT) | — | The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.cited 35× |
| melatonin supplementation | Increases - higher | quantitative insulin sensitivity check index | Human | patients under methadone maintenance treatment (MMT) | — | The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.cited 35× |
| melatonin supplementation | Decreases - had significantly lower | serum insulin levels | Human | patients under methadone maintenance treatment (MMT) | — | The effects of melatonin supplementation on mental health, metabolic and genetic profiles in patients under methadone maintenance treatment.cited 35× |
| melatonin supplementation | Decreases - significantly decreased | homeostasis model of assessment-insulin resistance (HOMA-IR) | Human | patients with PD | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial.cited 53× |
| melatonin supplementation | Decreases - significantly decreased | serum insulin levels | Human | patients with PD | 10 mg melatonin (two 5 mg capsules) once daily before bedtime. | Melatonin supplementation and the effects on clinical and metabolic status in Parkinson's disease: A randomized, double-blind, placebo-controlled trial.cited 53× |
| melatonin supplementation | Decreases - significantly reduced | homeostatic model assessment of insulin resistance (HOMA-IR) | Human | — | Not specified in the abstract. | The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 33× |
| melatonin supplementation | Decreases - significantly reduced | homeostatic model assessment of insulin resistance (HOMA-IR) | Human | patients with metabolic diseases | Not specified in the abstract. | The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 33× |
| melatonin supplementation | Increases - significantly increased | insulin levels | Human | — | Not specified in the abstract. | The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 33× |
| melatonin supplementation | Increases - significantly increased | insulin levels | Human | patients with metabolic diseases | Not specified in the abstract. | The Effects of Melatonin Supplementation on Glycemic Control: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.cited 33× |
| melatonin supplementation | No effect - no significant changes | insulin levels | Human | RA patients | 6 mg/day | Effects of melatonin supplementation on disease activity, oxidative stress, inflammatory, and metabolic parameters in patients with rheumatoid arthritis: a randomized double-blind placebo-controlled trial.cited 10× |
| melatonin supplementation | No effect - no evidence that ... improved | insulin resistance (HOMA-IR) | Human | healthy women aged 55 years and older with insomnia | 2 mg melatonin every night. | Melatonin Supplementation for Six Weeks Had No Effect on Arterial Stiffness and Mitochondrial DNA in Women Aged 55 Years and Older with Insomnia: A Double-Blind Randomized Controlled Study.cited 7× |
| melatonin supplementation | Decreases - reduced | insulin resistance | Human | patients with type 2 diabetes | Not available | Molecular Mechanisms of the Melatonin Receptor Pathway Linking Circadian Rhythm to Type 2 Diabetes Mellitus. |
| melatonin supplementation | Decreases - reduced | insulin resistance | Human | patients with type 2 diabetes | Not available | Molecular Mechanisms of the Melatonin Receptor Pathway Linking Circadian Rhythm to Type 2 Diabetes Mellitus. |
| melatonin supplementation | No effect - showed no significant results in | insulin resistance and glycated hemoglobin | Human | — | Not specified in the abstract. | Effects of melatonin supplementation on diabetes: A systematic review and meta-analysis of randomized clinical trials.cited 25× |
| melatonin receptors | Decreases - exert inhibitory effects | insulin secretion | Animal | — | — | Distribution of melatonin receptors in murine pancreatic islets. |
| 2 mg of sustained-release melatonin | No effect - did not significantly improve | insulin resistance | Human | rotating night shift workers | 2 mg sustained-release melatonin, administered at night or in the morning depending on shift schedule. | Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study.cited 5× |
| melatonin treatment at bedtime | No effect - does not significantly affect | insulin resistance | Human | rotating night shift workers | 2 mg sustained-release melatonin, administered at night or in the morning depending on shift schedule. | Effect of oral melatonin treatment on insulin resistance and diurnal blood pressure variability in night shift workers. A double-blind, randomized, placebo-controlled study.cited 5× |
| melatonin receptor knockout | No effect - altered | insulin levels | AnimalMolecular | wild-type vs receptor knockout mice of different ages (6 wk and 8-12 months old) | — | Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. |
| melatonin receptor knockout (MT1) | Increases - increased | plasma insulin levels | AnimalMolecular | MT1-knockout mice (8-12 months old) | — | Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. |
| melatonin receptor knockout (double) | Increases - increased | plasma insulin levels | AnimalMolecular | double-knockout mice (8-12 months old) | — | Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. |
| absence of melatonin during pregnancy | Decreases - apparent failure in | glucose-stimulated insulin secretion | Animal | rats | — | Melatonin regulates maternal pancreatic remodeling and B-cell function during pregnancy and lactation. |
| absence of melatonin during pregnancy | Decreases - dysregulation in | insulin secretion | Animal | rats | — | Melatonin regulates maternal pancreatic remodeling and B-cell function during pregnancy and lactation. |